Inclusion Criteria:

- Male and female patients aged above 18 years with histologically or cytologically
confirmed NSCLC and contrast-enhanced CT scan or Gadolinium-enhanced MRI confirmed
brain metastases who have a performance status of 0 to 2

- No previous radiotherapy, surgery or chemotherapy for brain metastases

- Patients should not have any unstable systemic disease

Exclusion Criteria:

- Serious abnormal laboratory values

- Evidence of severe or uncontrolled systemic disease or any concurrent condition which
in the Investigator's opinion makes it undesirable for the patient to participate in
the trial or which would jeopardize compliance with the protocol

- Clinically significant cardiovascular event (e.g. myocardial infarction, superior
vena cava syndrome (SVC), New York Heart Association (NYHA) classification of heart
disease >2 within 3 months before entry; or presence of cardiac disease that, in the

- Previous randomization of treatment in the present study and/ or current
participation in another clinical study